Sehar Toosy1, Ravinder Sodi2, Joseph M Pappachan3. 1. 1Lancaster University, Lancaster, LA1 4YW UK. 2. 2Department of Biochemistry and Blood Sciences, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, LA1 4RP UK. 3. 3Department of Endocrinology, Diabetes & Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Lincoln, PE21 9QS UK.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting women of reproductive age. Common features include menstrual irregularities, hyperandrogenism and polycystic ovarian morphology although the presentation can be heterogeneous. Insulin resistance is thought to be responsible for the hormonal and metabolic derangements observed. PCOS has two phenotypes, overweight/obese and lean, the latter being a much less common presentation of the syndrome. AIMS: The aim of the present review is to summarise cardinal features, and to devise diagnostic and treatment algorithms for lean PCOS based on recent literature. METHODS: We searched PubMed, EBSCOhost and Google Scholar using search terms such as 'lean polycystic ovary syndrome' OR 'lean polycystic ovarian syndrome' OR 'lean PCOS' OR 'lean polycystic ovary disease' OR 'lean polycystic ovarian disease' OR 'lean PCOD' OR 'hyperandrogenism' AND 'low BMI OR 'low body mass index' to identify potential articles to be included in the review. Citation searches were subsequently performed in order to find relevant literature. RESULTS: Hormonal, metabolic and haematological profiles were altered in lean women with PCOS compared to healthy counterparts. However, the derangements were either comparable or less obvious compared to obese women with the syndrome. Insulin resistance seemed inherent in PCOS independent of obesity. Treatment options included weight maintenance, restoration of ovulation with insulin-sensitizers such as metformin, relief of symptoms such as hirsutism, acne and menstrual dysfunction, and assisted reproductive technologies in refractory cases, all of which showed promising results. The literature with evidence on lean PCOS is of low to moderate quality and there are still some uncertainties in the evidence base. CONCLUSION: Carefully designed randomised controlled trials are required to confirm findings of previous studies in lean PCOS and to consolidate diagnostic and management algorithms proposed in this review. This paper will aid health professionals to improve their clinical approach in managing lean women with PCOS.
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting women of reproductive age. Common features include menstrual irregularities, hyperandrogenism and polycystic ovarian morphology although the presentation can be heterogeneous. Insulin resistance is thought to be responsible for the hormonal and metabolic derangements observed. PCOS has two phenotypes, overweight/obese and lean, the latter being a much less common presentation of the syndrome. AIMS: The aim of the present review is to summarise cardinal features, and to devise diagnostic and treatment algorithms for lean PCOS based on recent literature. METHODS: We searched PubMed, EBSCOhost and Google Scholar using search terms such as 'lean polycystic ovary syndrome' OR 'lean polycystic ovarian syndrome' OR 'lean PCOS' OR 'lean polycystic ovary disease' OR 'lean polycystic ovarian disease' OR 'lean PCOD' OR 'hyperandrogenism' AND 'low BMI OR 'low body mass index' to identify potential articles to be included in the review. Citation searches were subsequently performed in order to find relevant literature. RESULTS: Hormonal, metabolic and haematological profiles were altered in lean women with PCOS compared to healthy counterparts. However, the derangements were either comparable or less obvious compared to obese women with the syndrome. Insulin resistance seemed inherent in PCOS independent of obesity. Treatment options included weight maintenance, restoration of ovulation with insulin-sensitizers such as metformin, relief of symptoms such as hirsutism, acne and menstrual dysfunction, and assisted reproductive technologies in refractory cases, all of which showed promising results. The literature with evidence on lean PCOS is of low to moderate quality and there are still some uncertainties in the evidence base. CONCLUSION: Carefully designed randomised controlled trials are required to confirm findings of previous studies in lean PCOS and to consolidate diagnostic and management algorithms proposed in this review. This paper will aid health professionals to improve their clinical approach in managing lean women with PCOS.
Authors: Yuka Asai; Akerke Baibergenova; Maha Dutil; Shannon Humphrey; Peter Hull; Charles Lynde; Yves Poulin; Neil H Shear; Jerry Tan; John Toole; Catherine Zip Journal: CMAJ Date: 2015-11-16 Impact factor: 8.262
Authors: F Broglio; E Arvat; A Benso; C Gottero; G Muccioli; M Papotti; A J van der Lely; R Deghenghi; E Ghigo Journal: J Clin Endocrinol Metab Date: 2001-10 Impact factor: 5.958
Authors: Lourdes Ibáñez; Sharon E Oberfield; Selma Witchel; Richard J Auchus; R Jeffrey Chang; Ethel Codner; Preeti Dabadghao; Feyza Darendeliler; Nancy Samir Elbarbary; Alessandra Gambineri; Cecilia Garcia Rudaz; Kathleen M Hoeger; Abel López-Bermejo; Ken Ong; Alexia S Peña; Thomas Reinehr; Nicola Santoro; Manuel Tena-Sempere; Rachel Tao; Bulent O Yildiz; Haya Alkhayyat; Asma Deeb; Dipesalema Joel; Reiko Horikawa; Francis de Zegher; Peter A Lee Journal: Horm Res Paediatr Date: 2017-11-13 Impact factor: 2.852
Authors: Vu Ngoc Anh Ho; Toan Duong Pham; Nam Thanh Nguyen; Hieu Le Trung Hoang; Tuong Manh Ho; Lan Ngoc Vuong Journal: Clin Exp Reprod Med Date: 2022-05-27
Authors: Jia Zhu; Natàlia Pujol-Gualdo; Laura B L Wittemans; Cecilia M Lindgren; Triin Laisk; Joel N Hirschhorn; Yee-Ming Chan Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 6.134
Authors: Antonio Aversa; Sandro La Vignera; Rocco Rago; Alessandra Gambineri; Rossella E Nappi; Aldo E Calogero; Alberto Ferlin Journal: Front Endocrinol (Lausanne) Date: 2020-08-11 Impact factor: 5.555